摘要
目的应用表面增强激光解析电离飞行时间质谱(SELDI-TOF-MS)蛋白质芯片技术探讨联合前列腺特异抗原(PSA)早期诊断前列腺癌的方法。方法以病理确诊的45例前列腺癌和45例良性前列腺增生患者血清为研究对象,采用SELDI蛋白质芯片技术检测血清的蛋白表达图谱,分析差异蛋白,用酶联免疫吸附试验(ELISA)法检测血清PSA,对所得差异蛋白联合PSA进行分析。结果在前列腺癌和良性前列腺增生患者血清中检测到9个差异蛋白(P<0.01),前列腺癌患者差异蛋白7个高表达,2个低表达。联合相对分子质量3771.14和4481.59两个差异蛋白诊断前列腺癌,其敏感性为86.67%,特异性为88.89%。3771.14蛋白与血清PSA诊断前列腺癌具有很强的互补性。结论通过SELDI蛋白质芯片技术可以筛选出前列腺癌的潜在标志蛋白,多个差异蛋白联合检测可以提高前列腺癌诊断的敏感性和特异性;联合3771.14蛋白与血清PSA可以更好地早期诊断前列腺癌。
Objective To develop an approach combining surface-enhanced laser desorption ionization time- of-flight mass spectrometry （SELDI-TOF-MS） and prostate specific antigen （PSA） test for early diagnosis of prostate cancer. Methods The serum samples from pathologically confirmed patients with prostate cancer （n=45） or benign prostatic hyperplasia （BPH, n=45） were detected by SELDI-TOF-MS. The data of spectra were analyzed by bioinformatics tools Biomarker Wizard. PSA of these patients were detected by ELISA. The results were studied along with differential proteins detected. Results Compared with the spectra of BPH patients, there were 9 potential markers detected in the spectra of untreated prostate cancer patients （P〈0.01）, 7 with high-level expression and 2 with low-level expression. Combined detection of two biomarkers （M/Z 3771.14 and M/Z 4481.59） achieved 86.49 % sensitivity and 89.19 % specificity in diagnosis of prostate cancer. Protein （M/Z 3771.14） and PSA appeared to have strong eomplementation for diagnosis of prostate cancer. Conclusion SELDI-TOF-MS showed great potential for prostate cancer in early diagnosis and screening of tumor biomarkers. Combining several biomarkers to detect prostate cancer can improve sensitivity and specificity. Using protein 3771.14 and PSA could diagnose early prostate cancer more correctly.
出处
《中国药物与临床》
CAS
2009年第6期482-485,共4页
Chinese Remedies & Clinics
基金
山西省卫生厅科技攻关计划项目(200623)
关键词
前列腺肿瘤
早期诊断
蛋白质阵列分析
前列腺特异抗原
Prostatic neoplasms
Early diagnosis
Protein array analysis
Prostate-specific antigen
